They did that because they were dicking around trying to obtain that one dose for all (Alk and Egfr)
They wasted months and came up blank.
It is a shame because this drug (ponatinib) could have been something significant in the hands of competent drug developer. Aria clearly effed this up and now the company and its shareholders are decimated.
Saddest part is that there are patients that this drug could have truly helped.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.